See more : Surge Battery Metals Inc. (NILI.V) Income Statement Analysis – Financial Results
Complete financial analysis of Noble Corporation Plc (NE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Noble Corporation Plc, a leading company in the Oil & Gas Drilling industry within the Energy sector.
You may be interested
- Astron Paper & Board Mill Limited (ASTRON.NS) Income Statement Analysis – Financial Results
- Fawry For Banking Technology An (EGS745L1C014.CA) Income Statement Analysis – Financial Results
- B Communications Ltd (BCOM.TA) Income Statement Analysis – Financial Results
- Maiden Lane Jewelry, Ltd. (MDNL) Income Statement Analysis – Financial Results
- Byron Energy Limited (BYE.AX) Income Statement Analysis – Financial Results
Noble Corporation Plc (NE)
About Noble Corporation Plc
Noble Corporation, together with its subsidiaries, operates as an offshore drilling contractor for the oil and gas industry worldwide. The company provides contract drilling services to the oil and gas industry through its fleet of mobile offshore drilling units. As of February 16, 2022, it operated a fleet of 20 offshore drilling units, which included 12 floaters and 8 jackups. The company was formerly known as Noble Holding Corporation plc. Noble Corporation was founded in 1921 and is headquartered in Sugar Land, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.59B | 1.41B | 847.81M | 964.27M | 1.31B | 1.08B | 1.25B | 2.67B | 3.35B | 3.23B | 2.47B | 2.13B | 2.70B | 2.81B | 3.64B | 3.45B | 3.00B | 2.10B | 1.38B | 1.07B | 987.38M | 986.36M | 1.00B | 882.60M | 705.90M | 788.20M | 713.20M | 514.30M | 328.00M | 352.00M | 194.90M | 139.70M | 177.40M | 136.20M | 103.70M | 44.00M | 28.80M | 34.70M | 71.60M |
| Cost of Revenue | 1.85B | 1.11B | 855.13M | 989.80M | 1.19B | 1.15B | 1.21B | 1.53B | 1.93B | 2.19B | 1.18B | 992.29M | 1.48B | 1.26B | 1.11B | 1.13B | 1.13B | 883.92M | 756.82M | 677.13M | 594.95M | 559.26M | 475.17M | 479.41M | 422.90M | 456.50M | 387.10M | 331.50M | 240.00M | 243.20M | 128.60M | 103.90M | 131.40M | 112.10M | 81.80M | 37.30M | 25.40M | 29.60M | 54.90M |
| Gross Profit | 743.75M | 305.45M | -7.33M | -25.53M | 117.49M | -70.73M | 44.40M | 1.13B | 1.42B | 1.04B | 1.29B | 1.14B | 1.22B | 1.55B | 2.53B | 2.31B | 1.87B | 1.22B | 625.32M | 389.11M | 392.43M | 427.09M | 527.16M | 403.19M | 283.00M | 331.70M | 326.10M | 182.80M | 88.00M | 108.80M | 66.30M | 35.80M | 46.00M | 24.10M | 21.90M | 6.70M | 3.40M | 5.10M | 16.70M |
| Gross Profit Ratio | 28.73% | 21.60% | -0.86% | -2.65% | 9.00% | -6.53% | 3.55% | 42.44% | 42.29% | 32.25% | 52.25% | 53.52% | 45.23% | 55.14% | 69.49% | 67.10% | 62.30% | 57.91% | 45.24% | 36.49% | 39.74% | 43.30% | 52.59% | 45.68% | 40.09% | 42.08% | 45.72% | 35.54% | 26.83% | 30.91% | 34.02% | 25.63% | 25.93% | 17.69% | 21.12% | 15.23% | 11.81% | 14.70% | 23.32% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 128.41M | 82.18M | 68.20M | 121.20M | 168.79M | 73.22M | 71.63M | 69.26M | 76.84M | 106.77M | 118.00M | 99.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | -5.88M | 0.00 | -100.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 128.41M | 82.18M | 68.20M | 121.20M | 68.79M | 73.22M | 71.63M | 69.26M | 76.84M | 106.77M | 118.00M | 99.99M | 91.38M | 92.00M | 80.26M | 74.14M | 85.83M | 46.27M | 40.28M | 33.71M | 26.63M | 26.94M | 24.30M | 23.78M | 35.80M | 30.30M | 64.80M | 54.50M | 40.10M | 51.30M | 22.40M | 22.60M | 30.20M | 17.10M | 18.20M | 7.50M | 4.50M | 6.20M | 8.60M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 637.44M | 539.83M | 439.15M | 330.17M | 289.47M | 242.62M | 211.99M | 168.22M | 144.66M | 125.15M | 118.58M | 110.79M | 89.00M | 71.70M | 77.90M | 52.20M | 36.50M | 39.50M | 20.50M | 17.70M | 19.90M | 14.40M | 14.20M | 12.10M | 14.50M | 28.00M | 34.70M |
| Operating Expenses | 128.41M | 82.18M | 68.20M | 121.20M | 68.79M | 73.22M | 71.63M | 69.26M | 76.84M | 106.77M | 550.95M | 517.08M | 728.82M | 631.83M | 519.41M | 404.32M | 375.30M | 288.89M | 252.27M | 201.93M | 171.29M | 152.09M | 142.87M | 134.57M | 124.80M | 102.00M | 142.70M | 106.70M | 76.60M | 90.80M | 42.90M | 40.30M | 50.10M | 31.50M | 32.40M | 19.60M | 19.00M | 34.20M | 43.30M |
| Cost & Expenses | 2.01B | 1.19B | 923.34M | 1.11B | 1.26B | 1.23B | 1.28B | 1.60B | 2.01B | 2.30B | 1.73B | 1.51B | 2.21B | 1.89B | 1.63B | 1.54B | 1.50B | 1.17B | 1.01B | 879.06M | 766.24M | 711.36M | 618.04M | 613.98M | 547.70M | 558.50M | 529.80M | 438.20M | 316.60M | 334.00M | 171.50M | 144.20M | 181.50M | 143.60M | 114.20M | 56.90M | 44.40M | 63.80M | 98.20M |
| Interest Income | 18.07M | 14.37M | 11.34M | 9.01M | 272.94M | 8.30M | 5.45M | 18.00K | 36.29M | 0.00 | 2.75M | 5.19M | 1.48M | 9.89M | 6.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 59.14M | 42.72M | 31.96M | 164.65M | 279.44M | 297.61M | 291.99M | 222.92M | 213.85M | 155.18M | 106.30M | 85.76M | 55.73M | 9.46M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 301.35M | 146.88M | 110.16M | 374.13M | 440.22M | 486.53M | 547.99M | 611.07M | 634.31M | 627.47M | 511.42M | 440.62M | 658.64M | 539.83M | 408.31M | 356.66M | 292.99M | 253.33M | 241.75M | 209.12M | 182.59M | 154.47M | 141.50M | 110.79M | 89.00M | 71.70M | 77.90M | 52.20M | 36.50M | 39.50M | 20.50M | 17.70M | 19.90M | 14.40M | 14.20M | 12.10M | 14.50M | 28.00M | 34.70M |
| EBITDA | 872.73M | 381.10M | 34.63M | -3.70B | 388.76M | 345.56M | 390.17M | -578.88M | 1.97B | 812.12M | 1.39B | 1.05B | 1.15B | 1.47B | 2.43B | 2.27B | 1.80B | 1.19B | 625.63M | 405.33M | 369.57M | 397.79M | 490.51M | 337.09M | 203.70M | 302.60M | 450.80M | 153.50M | 41.40M | 66.70M | 43.90M | 8.40M | 6.80M | 7.00M | 4.50M | -1.20M | -2.30M | -54.10M | 3.70M |
| EBITDA Ratio | 33.71% | 26.82% | 4.08% | 24.52% | 37.45% | 31.64% | 41.62% | 62.76% | 58.92% | 48.36% | 48.11% | 49.34% | 42.95% | 52.22% | 66.63% | 65.84% | 59.49% | 55.93% | 43.83% | 34.79% | 37.43% | 40.33% | 48.94% | 38.19% | 28.86% | 38.39% | 63.21% | 29.85% | 12.62% | 18.95% | 22.52% | 6.01% | 3.83% | 5.14% | 4.34% | -2.73% | -7.99% | -155.91% | 5.17% |
| Operating Income | 574.71M | 228.77M | -75.53M | -137.72M | 48.70M | -143.94M | -27.23M | 1.06B | 1.34B | 935.66M | 677.86M | 612.69M | 490.49M | 916.08M | 2.01B | 1.91B | 1.49B | 927.43M | 373.05M | 187.17M | 221.14M | 275.00M | 384.29M | 268.62M | 158.20M | 229.70M | 183.40M | 76.10M | 11.40M | 18.00M | 23.40M | -4.50M | -4.10M | -7.40M | -10.50M | -12.90M | -15.60M | -29.10M | -26.60M |
| Operating Income Ratio | 22.20% | 16.18% | -8.91% | -14.28% | 3.73% | -13.29% | -2.18% | 39.85% | 39.99% | 28.95% | 27.42% | 28.70% | 18.19% | 32.63% | 55.23% | 55.37% | 49.77% | 44.16% | 26.99% | 17.55% | 22.40% | 27.88% | 38.34% | 30.44% | 22.41% | 29.14% | 25.72% | 14.80% | 3.48% | 5.11% | 12.01% | -3.22% | -2.31% | -5.43% | -10.13% | -29.32% | -54.17% | -83.86% | -37.15% |
| Total Other Income/Expenses | -62.46M | -37.27M | 293.74M | -162.32M | -242.81M | -291.10M | -286.54M | -2.03B | -598.28M | -906.19M | -102.12M | 90.53M | -54.24M | 429.00K | 5.16M | 4.06M | -1.96M | -6.14M | -8.95M | -25.36M | -34.15M | -31.68M | -34.30M | -42.32M | -32.70M | 1.20M | 196.20M | 25.90M | -6.50M | 9.20M | -1.80M | -1.40M | -7.20M | 0.00 | 800.00K | -400.00K | -1.20M | -53.00M | -4.40M |
| Income Before Tax | 512.24M | 191.50M | 356.00M | -4.24B | -909.09M | -1.24B | -449.81M | -967.03M | 742.43M | 29.47M | 638.42M | 543.37M | 436.25M | 916.51M | 2.02B | 1.91B | 1.49B | 921.29M | 364.09M | 161.82M | 186.98M | 243.33M | 349.99M | 226.31M | 125.50M | 230.90M | 379.60M | 102.00M | 4.90M | 27.20M | 21.60M | -5.90M | -11.30M | -7.40M | -9.70M | -13.30M | -16.80M | -82.10M | -31.00M |
| Income Before Tax Ratio | 19.79% | 13.54% | 41.99% | -439.59% | -69.64% | -114.25% | -35.95% | -36.26% | 22.15% | 0.91% | 25.83% | 25.45% | 16.18% | 32.65% | 55.37% | 55.49% | 49.71% | 43.87% | 26.34% | 15.18% | 18.94% | 24.67% | 34.92% | 25.64% | 17.78% | 29.29% | 53.22% | 19.83% | 1.49% | 7.73% | 11.08% | -4.22% | -6.37% | -5.43% | -9.35% | -30.23% | -58.33% | -236.60% | -43.30% |
| Income Tax Expense | 30.34M | 22.55M | 3.79M | -260.40M | -38.54M | -106.64M | 42.63M | -109.16M | 159.23M | 106.65M | 92.12M | 95.18M | 72.63M | 143.08M | 337.26M | 351.46M | 282.89M | 189.42M | 67.40M | 15.73M | 20.57M | 33.82M | 86.08M | 60.75M | 30.20M | 68.90M | 115.70M | 22.70M | 3.30M | 5.70M | 2.50M | 2.20M | 2.10M | 1.40M | 800.00K | -4.90M | -6.70M | -38.10M | -14.50M |
| Net Income | 481.90M | 168.95M | 352.21M | -3.98B | -700.59M | -885.05M | -516.51M | -929.58M | 499.79M | 8.49M | 469.32M | 409.08M | 370.90M | 773.43M | 1.68B | 1.56B | 1.21B | 731.87M | 296.70M | 146.09M | 166.42M | 209.50M | 262.92M | 165.55M | 84.50M | 162.00M | 257.20M | 78.60M | 1.60M | 21.50M | 20.90M | -11.50M | -15.20M | -8.80M | -10.50M | -8.40M | -10.10M | -44.00M | -16.50M |
| Net Income Ratio | 18.61% | 11.95% | 41.54% | -412.59% | -53.67% | -81.74% | -41.28% | -34.86% | 14.91% | 0.26% | 18.99% | 19.16% | 13.76% | 27.55% | 46.11% | 45.29% | 40.26% | 34.85% | 21.47% | 13.70% | 16.85% | 21.24% | 26.23% | 18.76% | 11.97% | 20.55% | 36.06% | 15.28% | 0.49% | 6.11% | 10.72% | -8.23% | -8.57% | -6.46% | -10.13% | -19.09% | -35.07% | -126.80% | -23.04% |
| EPS | 3.48 | 1.99 | 5.85 | -15.86 | -2.81 | -3.59 | -2.11 | -3.82 | 2.06 | 0.03 | 1.85 | 1.62 | 1.48 | 3.06 | 6.51 | 5.90 | 4.52 | 5.38 | 2.18 | 1.10 | 1.26 | 1.58 | 1.98 | 0.62 | 0.32 | 0.62 | 0.97 | 0.36 | 0.01 | 0.14 | 0.17 | -0.17 | -0.22 | -0.18 | -0.25 | -0.21 | -0.36 | -1.95 | -0.71 |
| EPS Diluted | 3.32 | 1.73 | 5.85 | -15.86 | -2.81 | -3.59 | -2.11 | -3.82 | 2.06 | 0.03 | 1.85 | 1.62 | 1.47 | 3.05 | 6.48 | 5.85 | 4.48 | 5.33 | 2.16 | 1.09 | 1.25 | 1.57 | 1.96 | 0.61 | 0.32 | 0.62 | 0.97 | 0.36 | 0.01 | 0.14 | 0.17 | -0.17 | -0.22 | -0.18 | -0.25 | -0.21 | -0.36 | -1.95 | -0.71 |
| Weighted Avg Shares Out | 138.38M | 85.06M | 60.17M | 250.79M | 248.95M | 246.61M | 244.74M | 243.13M | 242.15M | 252.91M | 253.54M | 252.79M | 251.41M | 253.12M | 258.04M | 264.78M | 266.82M | 136.03M | 136.10M | 132.81M | 132.08M | 132.60M | 132.79M | 266.55M | 264.06M | 261.29M | 263.79M | 216.72M | 140.00M | 158.18M | 123.48M | 68.68M | 67.66M | 50.29M | 42.00M | 40.00M | 28.45M | 22.56M | 23.40M |
| Weighted Avg Shares Out (Dil) | 145.20M | 97.61M | 60.17M | 250.79M | 248.95M | 246.61M | 244.74M | 243.13M | 242.15M | 252.91M | 253.55M | 252.79M | 251.99M | 253.94M | 258.89M | 266.81M | 269.20M | 137.31M | 137.36M | 134.02M | 133.13M | 133.44M | 134.14M | 270.79M | 264.06M | 263.41M | 266.53M | 220.00M | 140.00M | 158.18M | 123.48M | 68.68M | 67.66M | 50.29M | 42.00M | 40.00M | 28.45M | 22.56M | 23.40M |
Intelligent Bio Solutions to Participate in the Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble...
BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 21, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been...
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company's management will be attending and presenting at the Noble Capital Markets...
Post-Election Insider Buying in These 6 Stocks Is Huge
24/7 Wall St. Insights As we race toward the end of the year, the past week brought some huge insider share purchases.
Noble Roman's Announces Third Quarter 2024 Financial Data
INDIANAPOLIS, IN / ACCESSWIRE / November 13, 2024 / Noble Roman's, Inc. (OTCQB:NROM), the Indianapolis based franchisor and licensor of Noble Roman's Pizza and Noble Roman's Craft Pizza & Pub ("CPP"), today announced financial data for the third quarter 2024...
Noble Roman's to Release 3rd Quarter 2024 Financial Data on November 13th; to Host Conference Call on November 14th at 4:00 PM EST
INDIANAPOLIS, IN / ACCESSWIRE / November 13, 2024 / Noble Roman's, Inc. (OTCQB:NROM), the Indianapolis based franchisor and licensor of Noble Roman's Pizza and Noble Roman's Craft Pizza & Pub, announced that it will report 2024 3rd quarter financial data...
Noble Capital Markets Initiates Equity Research Coverage on Zomedica
ANN ARBOR, MI / ACCESSWIRE / November 12, 2024 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, is pleased to announce that Noble Capital Markets has initiated company-sponsored...
Graham price target raised to $45 from $35 at Noble Capital
Noble Capital raised the firm's price target on Graham to $45 from $35 and keeps an Outperform rating on the shares. Graham's Q2 results exceeded expectations as "strong" sales growth, along with "exceptional execution throughout the business," drove meaningful margin...
Noble Corporation: Production Backlog And Capital Return Promising, Yet Low Visibility On Earnings Past 2025
Noble Corporation's geographic diversification and strong client base are positives, but its lack of long-term contracts and idle rigs are concerning. The company's fluctuating revenues and earnings, coupled with high operating costs for idle rigs, present significant financial risks. Despite...
Noble Corporation plc (NE) Q3 2024 Earnings Call Transcript
Noble Corporation plc (NYSE:NE ) Q3 2024 Earnings Conference Call November 6, 2024 9:00 AM ET Company Participants Ian MacPherson - Vice President of Investor Relations Robert Eifler - President and Chief Executive Officer Richard Barker - Chief Financial Officer...
Source: https://incomestatements.info
Category: Stock Reports